MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.275
-0.355
-9.78%
After Hours: 3.280 +0.005 +0.15% 16:41 03/05 EST
OPEN
3.600
PREV CLOSE
3.630
HIGH
3.670
LOW
2.980
VOLUME
865.27K
TURNOVER
--
52 WEEK HIGH
9.86
52 WEEK LOW
1.490
MARKET CAP
101.56M
P/E (TTM)
-2.8409
1D
5D
1M
3M
1Y
5Y
Recro to Present at H.C. Wainwright Global Life Science Conference
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral soli...
GlobeNewswire · 5d ago
DJ Recro Pharma, Inc. CEO David Enloe on Q4 2020 Results -- Earnings Call Transcript >REPH
Dow Jones · 02/28 05:01
8-K: Recro Pharma, Inc.
(EDGAR Online via COMTEX) -- false 0001588972 0001588972 2021-02-26 2021-02-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/27 08:08
Global Meloxicam Market Research Report 2020-2026
Feb 27, 2021 (Heraldkeepers) -- The global Meloxicam market is valued at US$ xx million in 2019 is expected to reach US$ xx million by the end of 2026,...
Heraldkeepers · 02/27 07:16
Mid-Afternoon Market Update: Crude Oil Down Over 3%; AMC Networks Shares Surge After Q4 Results
Toward the end of trading Friday, the Dow traded down 0.94% to 31,107.12 while the NASDAQ rose 1.25% to 13,283.53. The S&P also rose, gaining 0.15% to 3,835.15.
Benzinga · 02/26 19:50
FSR, OCGN, VST and ZYXI among midday movers
Gainers: Xtant Medical (XTNT) +189%.Intrusion (INTZ) +33%.Armstrong Flooring (AFI) +28%.Just Energy Group (JE) +28%.AMC Networks (AMCX) +26%.Applied UV (AUVI) +24%.Fisker (FSR) +21%.Ocugen (OCGN) +20%.Select Medical (SEM) +19%.Rubius Therapeutics (RUBY) +1...
Seekingalpha · 02/26 17:40
Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet
Midway through trading Friday, the Dow traded down 0.69% to 31,184.21 while the NASDAQ rose 0.95% to 13,243.64. The S&P also rose, gaining 0.21% to 3,837.28.
Benzinga · 02/26 17:17
Xtant Medical, Sensus Healthcare leads healthcare gainers; Tricida, Recro Pharma among major losers
Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%, NLS Pharmaceutics (NLS...
Seekingalpha · 02/26 16:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REPH. Analyze the recent business situations of Recro Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REPH stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 155
Institutional Holdings: 18.67M
% Owned: 60.21%
Shares Outstanding: 31.01M
TypeInstitutionsShares
Increased
20
2.39M
New
26
-257.35K
Decreased
21
1.64M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Wayne Weisman
President/Chief Executive Officer/Director
David Enloe
President/Chief Executive Officer/Director
J. David Enloe
Chief Financial Officer
Ryan Lake
Executive Vice President
Jyrki Mattila
Independent Director
William Ashton
Independent Director
Michael Berelowitz
Independent Director
Winston Churchill
Independent Director
James Miller
Independent Director
Bryan Reasons
No Data
About REPH
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPH stock methods without spending real money on the virtual paper trading platform.